For example, Phase I and II clinical trials have shown that the PARP inhibitor olaparib (AZD2281) can elicit significant and sustained anti-tumour responses, especially in familial cancer patients with BRCA1 or BRCA2 mutant tumours [reviewed in (Lord & Ashworth, 2012)]. Here, BRCA1 is linked to neoplasm.